Key Points
- AngioDynamics CFO Stephen Trowbridge sold 23,615 shares at an average price of $12.27, generating approximately $289,756. The transaction reduced his holdings by 7.77% to 280,461 shares.
- AngioDynamics shares opened at $11.99 after declining 2.9%, with a market capitalization of about $504 million. In its latest quarter, the company reported a smaller-than-expected loss of $0.04 per share and revenue of $80.92 million.
- Analyst opinions remain mixed, but the stock carries a consensus “Moderate Buy” rating and a $19.00 target price. Institutional investors and hedge funds own approximately 89.43% of the company.
AngioDynamics, Inc. (NASDAQ:ANGO - Get Free Report) CFO Stephen Trowbridge sold 1,720 shares of the business's stock in a transaction that occurred on Wednesday, October 28th. The stock was sold at an average price of $12.17, for a total transaction of $20,932.40. Following the sale, the chief financial officer owned 304,076 shares of the company's stock, valued at approximately $3,700,604.92. This represents a 0.56% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.
AngioDynamics Stock Down 2.9%
AngioDynamics stock opened at $11.99 on Friday. The firm has a fifty day moving average of $14.18 and a 200-day moving average of $12.47. AngioDynamics, Inc. has a 52-week low of $9.39 and a 52-week high of $16.29. The firm has a market capitalization of $504.23 million, a P/E ratio of -15.37 and a beta of 0.30.
AngioDynamics (NASDAQ:ANGO - Get Free Report) last posted its earnings results on Thursday, October 8th. The medical instruments supplier reported ($0.04) earnings per share for the quarter, beating the consensus estimate of ($0.11) by $0.07. The business had revenue of $80.92 million for the quarter, compared to analyst estimates of $80.51 million. AngioDynamics had a negative net margin of 10.12% and a negative return on equity of 4.49%. AngioDynamics has set its FY 2027 guidance at -0.290--0.240 EPS. On average, research analysts expect that AngioDynamics, Inc. will post -0.26 EPS for the current fiscal year.
Analyst Upgrades and Downgrades
Several research analysts have commented on the company. Wall Street Zen lowered AngioDynamics from a "buy" rating to a "hold" rating in a research report on Saturday, October 10th. HC Wainwright decreased their target price on AngioDynamics from $19.00 to $18.00 and set a "buy" rating for the company in a research report on Tuesday, October 13th. Zacks Research upgraded AngioDynamics from a "strong sell" rating to a "hold" rating in a research note on Monday, October 5th. Canaccord Genuity Group reiterated a "buy" rating and set a $20.00 target price on shares of AngioDynamics in a report on Friday, October 9th. Finally, Weiss Ratings reissued a "sell (d-)" rating on shares of AngioDynamics in a research report on Thursday, October 15th. One investment analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average price target of $19.00.
Get Our Latest Report on ANGO
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently made changes to their positions in the company. Pinnacle Wealth Planning Services Inc. purchased a new stake in AngioDynamics during the 3rd quarter worth $40,000. Integrated Wealth Concepts LLC acquired a new position in AngioDynamics in the 2nd quarter worth $38,000. Legal & General Group Plc acquired a new position in AngioDynamics in the 2nd quarter worth $45,000. Public Employees Retirement System of Ohio acquired a new position in AngioDynamics in the 2nd quarter worth $64,000. Finally, Arrowstreet Capital Limited Partnership boosted its position in AngioDynamics by 0.7% in the 1st quarter. Arrowstreet Capital Limited Partnership now owns 758,450 shares of the medical instruments supplier's stock valued at $8,624,000 after buying an additional 5,509 shares during the last quarter. 89.43% of the stock is currently owned by hedge funds and other institutional investors.
AngioDynamics Company Profile
(
Get Free Report)
AngioDynamics, Inc is a medical technology company that develops and manufactures minimally invasive devices used in vascular access, peripheral vascular disease treatment, oncology and surgical procedures. Its products are designed to support physicians in diagnosing and treating patients while reducing the need for more invasive interventions.
The company's portfolio includes the Auryon system for atherectomy and thrombectomy procedures, the NanoKnife system, which uses irreversible electroporation technology for the ablation of certain soft-tissue tumors, and devices for vascular access and the management of procedure-related complications.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
